세계의 의약품 수탁제조 시장 : 서비스별(의약품 시장 개척, 의약품, 생물학적 제제, 포장 및 라벨링, 완제), 최종사용자별, 지역별 - 예측(-2029년)
Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule, Oral Liquid), Biologics (API, FDF), Packaging & Labelling, Fill-finish), End Users - Global Forecasts to 2029
세계 의약품 수탁제조 시장 규모는 2024년 2,009억 달러에서 2029년 3,196억 달러에 달할 것으로 예상되며, 2024년부터 2029년까지 예측 기간 동안 9.7%의 CAGR을 기록할 것으로 예상됩니다.
의약품 수탁제조 시장의 확대는 주로 비용 효율적인 제네릭 의약품에 대한 수요 증가와 일반 의약품의 특허 만료가 다가오고 있기 때문입니다. 이로 인해 기업들은 주요 기능에 우선순위를 두게 되었고, 위탁 제조 서비스에 대한 수요가 증가하면서 시장 성장이 가속화되고 있습니다.
| 조사 범위 |
| 조사 대상 연도 |
2022-2029년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(10억 달러) |
| 부문 |
서비스별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 중남미, 중동 및 아프리카 |
서비스별로는 의약품 개발 서비스, 의약품 제조 서비스, 생물학적 제제 제조 서비스, 포장 및 라벨링 서비스, 완제 서비스, 기타 서비스로 의약품 수탁제조 시장을 구분하고 있으며, 2024-2029년 예측 기간 동안 생물학적 제제 제조 서비스 분야가 가장 높은 연평균 성장률을 기록할 것으로 예상됩니다. 이러한 성장은 생물학적 제제 및 표적 약리요법에 대한 수요 증가와 세포 및 유전자 치료제 파이프라인에서 수행되는 임상시험의 증가에 기인하는 것으로 보입니다. 이러한 이유로 부문별 성장이 긍정적으로 작용할 가능성이 높습니다.
의약품 수탁제조 시장 세분화에는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카가 포함되며, 2023년 북미가 의약품 개발 및 위탁생산 시장에서 압도적인 점유율을 차지했습니다. 이 지역의 우위는 이 지역의 주요 기업의 존재와 진행 중인 의약품 R&D 및 제조 위탁 등 다양한 요인에 기인합니다. 맞춤형 의약품에 대한 인식의 증가, 제네릭 의약품에 대한 신흥국 정부의 노력, 제약 R&D 및 위탁생산 시장에 새로 진입하는 기업들로 인해 아시아태평양의 성장 속도는 더욱 빨라질 것으로 예상됩니다.
이 보고서는 세계 의약품 수탁제조 시장을 조사하여 서비스별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 정리한 보고서입니다.
목차
제1장 소개
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
- 소개
- 시장 역학
- 가격 분석
- 밸류체인 분석
- 공급망 분석
- 생태계 분석
- 기술 분석
- Porter's Five Forces 분석
- 규제 상황
- 2024-2025년의 주요 회의와 이벤트
- 주요 이해관계자와 구입 기준
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 약식 신약 신청(ANDA) 승인
- 투자와 자금 조달 시나리오
- AI/생성형 AI가 의약품 수탁제조 시장에 미치는 영향
제6장 의약품 수탁제조 시장(서비스별)
- 소개
- 의약품 제조 서비스
- 의약품 개발 서비스
- 생물학적 제제 제조 서비스
- 포장 및 라벨링 서비스
- 완제 서비스
- 기타 서비스
제7장 의약품 수탁제조 시장(최종사용자별)
- 소개
- 대형 제약회사
- 중소규모 제약회사
- 제네릭 의약품 회사
- 기타
제8장 의약품 수탁제조 시장(지역별)
- 소개
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 상황
- 소개
- 주요 진출 기업 전략/비책
- 매출 분석
- 시장 점유율 분석
- 기업 평가 매트릭스 : 주요 진출 기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 브랜드/서비스 비교
- 기업 가치 평가와 재무 지표
- 경쟁 시나리오
제10장 기업 개요
- 주요 진출 기업
- THERMO FISHER SCIENTIFIC INC.
- LONZA
- CATALENT, INC.
- WUXI APPTEC
- WUXI BIOLOGICS
- SAMSUNG BIOLOGICS
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- EVONIK INDUSTRIES AG
- FUJIFILM HOLDINGS CORPORATION
- ABBVIE INC.
- SIEGFRIED HOLDING AG
- MERCK KGAA
- ALMAC GROUP
- CHARLES RIVER LABORATORIES
- ASYMCHEM INC.
- VETTER PHARMA
- ALCAMI CORPORATION
- 기타 기업
- PIRAMAL PHARMA SOLUTIONS
- SYNGENE INTERNATIONAL LIMITED
- CAMBREX CORPORATION
- JUBILANT BIOSYS LTD.
- YUHAN CORPORATION
- PIERRE FABRE GROUP
- PFIZER CENTREONE
- DELPHARM
- FRONTAGE LABS
- SHARP SERVICES, LLC
- GRAND RIVER ASEPTIC MANUFACTURING
제11장 부록
ksm
The global pharmaceutical contract manufacturing market is projected to reach USD 319.6 billion by 2029 from USD 200.9 billion in 2024, at a CAGR of 9.7% during the forecast period of 2024 to 2029. The expansion of the pharmaceutical contract manufacturing market has been primarily propelled by the rising need for generic drugs, which are cost-effective, and the approaching expiration of patents for popular medications. This has compelled companies to prioritize their main functions, leading to increased demand for contract manufacturing services and accelerating the growth of the market.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD Billion) |
| Segments | Service, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
"The biologics manufacturing services segment is anticipated to experience the highest compound annual growth rate (CAGR) over the period of forecasting that spans from 2024 to 2029."
Based on service, the drug development services, pharmaceutical manufacturing services, biologics manufacturing services, packaging and labelling services, fill-finish services, and other services segment the pharmaceutical contract manufacturing market. It is anticipated that the biologics manufacturing services segment would grow at the highest compound annual growth rate (CAGR) over the period of forecasting in 2024-2029. The growth can be due to the increasing demand for biologics and targeted pharmacological therapies, as well as the rise in the number of studies that are being conducted in the pipeline for cell and gene therapy. Because of these reasons, there is a good chance that segmental growth will be positively affected.
"The growth of the Asia Pacific pharmaceutical contract manufacturing market is likely to be at faster pace during the period of the forecast from 2024-2029."
The segmentations of the pharmaceutical contract manufacturing market include North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa. In 2023, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract Development and Manufacturing. With increasing awareness about personalized therapeutics, growing initiatives in the region by governments for generics medicines, and the entry of new participants into the pharmaceutical contract development and manufacturing market, the pace of growth in the Asia Pacific region is likely to be faster.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 60% and Demand Side 40%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (US)
- Catalent, Inc. (US)
- Lonza Group (Switzerland)
- AbbVie, Inc. (US)
- WuXi Apptec (China)
- WuXi Biologics (China)
- Merck KGaA (Germany)
- Siegfried Holding AG (Switzerland)
- Evonik Industries AG (Germany)
- Boehringer Ingelheim International (Germany)
- FUJIFILM Holding Corporation (Japan)
- Samsung Biologics (South Korea)
- Almac Group (UK)
- Vetter Pharma (Germany)
- Alcami Corporation (US)
- Asychem Inc. (China)
- Charles River Laboratories (US)
- Piramal Pharma Solutions (India)
- Syngene (Biocon Limited) (India)
- Delpharm Holdings (France)
- Yuhan Corporation (South Korea)
- Cambrex Corporation. (US)
- Sharp Services, LLC (US)
- Grand River Aseptic Manufacturing (US)
- Jubilant Biosys Ltd. (India)
- Pierre Fabre group (France)
- pfizer centerOne (US)
- Frontage Labs (US)
Research Coverage:
This research report categorizes the pharmaceutical contract manufacturing market by service (drug development services, pharmaceutical manufacturing services (pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services), packaging & labelling services, fill-finish services, other services)), end user (big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, others), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.
Key Benefits of Buying the Report:
The report will assist market leaders and new entrants by providing them with the most accurate estimates of the revenue figures for the entire pharmaceutical contract manufacturing market and its subsegments. Moreover, examining subsegments would improve stakeholders' understanding of the competitive landscape and offer them vital insights to effectively position their company and formulate suitable go-to-market strategies. The objective of this research is to provide stakeholders with a clear understanding of the current market situation. This will be achieved by presenting them with detailed information about the main aspects that impact the industry, such as drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.
- Service Development/Innovation: Thorough investigation of lately launched services available in the pharmaceutical contract manufacturing market.
- Market Development: By means of analysis of regional market trends, the study offers comprehensive knowledge on profitable markets.
- Market Diversification: Comprehensive information on new services, underdeveloped areas, present developments, and pharmaceutical contract manufacturing sector investments is what markets diversification is based on.
- Competitive Assessment: A comprehensive evaluation of the market shares, growth strategies, and service offerings of prominent companies such as Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China), and others in the pharmaceutical contract development and manufacturing market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED
- 1.3.3 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
- 1.5.1 IMPACT OF AI/GEN AI
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.2 INSIGHTS FROM PRIMARY SOURCES
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
- 4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE & COUNTRY, 2023
- 4.3 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
- 4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
- 4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increased investments in precision medicines
- 5.2.1.2 Rising demand for generic drugs
- 5.2.1.3 Need for affordable drug development
- 5.2.1.4 Favorable initiatives by contract development and manufacturing organizations
- 5.2.2 RESTRAINTS
- 5.2.2.1 Stringent regulatory requirements
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Emergence of cell and gene therapies
- 5.2.3.2 Growing inclination toward one-stop-shop model
- 5.2.3.3 Growth opportunities in emerging countries
- 5.2.3.4 Booming nuclear medicine market
- 5.2.4 CHALLENGES
- 5.2.4.1 Introduction of serialization
- 5.2.4.2 Intellectual property risk
- 5.3 PRICING ANALYSIS
- 5.3.1 INDICATIVE PRICING ANALYSIS, BY SERVICE
- 5.3.2 INDICATIVE PRICING ANALYSIS, BY REGION
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 ECOSYSTEM ANALYSIS
- 5.7 TECHNOLOGY ANALYSIS
- 5.7.1 KEY TECHNOLOGIES
- 5.7.1.1 Single-use bioprocessing systems
- 5.7.1.2 Continuous manufacturing
- 5.7.1.3 Advanced formulation technologies
- 5.7.2 COMPLEMENTARY TECHNOLOGIES
- 5.7.2.1 High-performance liquid chromatography
- 5.7.2.2 Mass spectrometry
- 5.7.2.3 Next-generation sequencing
- 5.7.2.4 Automation and robotics
- 5.7.2.5 Process analytical technology
- 5.7.3 ADJACENT TECHNOLOGIES
- 5.7.3.1 3D printing
- 5.7.3.2 Artificial intelligence and machine learning
- 5.8 PORTER'S FIVE FORCES ANALYSIS
- 5.8.1 THREAT OF NEW ENTRANTS
- 5.8.2 THREAT OF SUBSTITUTES
- 5.8.3 BARGAINING POWER OF SUPPLIERS
- 5.8.4 BARGAINING POWER OF BUYERS
- 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.9 REGULATORY LANDSCAPE
- 5.9.1 REGULATORY SCENARIO
- 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10 KEY CONFERENCES AND EVENTS, 2024-2025
- 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.11.2 BUYING CRITERIA
- 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.13 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
- 5.14 INVESTMENT AND FUNDING SCENARIO
- 5.15 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
- 6.1 INTRODUCTION
- 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
- 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
- 6.2.1.1 Rising cases of patent expiry to fuel market
- 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
- 6.2.2.1 Parenteral manufacturing services
- 6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support market growth
- 6.2.2.2 Tablet manufacturing services
- 6.2.2.2.1 Growing domestic production capacity in emerging markets to accelerate growth
- 6.2.2.3 Capsule manufacturing services
- 6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth
- 6.2.2.4 Oral liquid manufacturing services
- 6.2.2.4.1 Growing preference for oral liquids over powders to facilitate growth
- 6.2.2.5 Semi-solid manufacturing services
- 6.2.2.5.1 Rising prevalence of skin infections and burns to propel market
- 6.2.2.6 Other FDF manufacturing services
- 6.3 DRUG DEVELOPMENT SERVICES
- 6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
- 6.4 BIOLOGICS MANUFACTURING SERVICES
- 6.4.1 BIOLOGICS API MANUFACTURING SERVICES
- 6.4.1.1 Expanding offerings in cell line development and production to aid market growth
- 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
- 6.4.2.1 Growing importance due to therapeutic potential to encourage growth
- 6.5 PACKAGING & LABELING SERVICES
- 6.5.1 INCREASING STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR MARKET GROWTH
- 6.6 FILL-FINISH SERVICES
- 6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO DRIVE MARKET
- 6.7 OTHER SERVICES
7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
- 7.1 INTRODUCTION
- 7.2 BIG PHARMACEUTICAL COMPANIES
- 7.2.1 RISING PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO MARKET GROWTH
- 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
- 7.3.1 NEED TO SAVE COSTS ON IN-HOUSE DRUG MANUFACTURING TO BOOST MARKET
- 7.4 GENERIC PHARMACEUTICAL COMPANIES
- 7.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
- 7.5 OTHER END USERS
8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
- 8.1 INTRODUCTION
- 8.2 NORTH AMERICA
- 8.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 8.2.2 US
- 8.2.2.1 Presence of major pharmaceutical companies to drive market
- 8.2.3 CANADA
- 8.2.3.1 Favorable government support to sustain market growth
- 8.3 EUROPE
- 8.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 8.3.2 GERMANY
- 8.3.2.1 Free drug pricing policy to speed up market growth
- 8.3.3 UK
- 8.3.3.1 Favorable R&D funding scenario to augment growth
- 8.3.4 FRANCE
- 8.3.4.1 Booming life science research to fuel market
- 8.3.5 ITALY
- 8.3.5.1 Rising commercial drug development to favor growth
- 8.3.6 SWITZERLAND
- 8.3.6.1 Role as global pharmaceutical manufacturing hub to fuel market
- 8.3.7 POLAND
- 8.3.7.1 Universal health coverage and advanced infrastructure to encourage growth
- 8.3.8 SPAIN
- 8.3.8.1 Growing outsourcing of development and trial phases to boost market
- 8.3.9 REST OF EUROPE
- 8.4 ASIA PACIFIC
- 8.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 8.4.2 CHINA
- 8.4.2.1 Made in China 2025 initiative to aid market growth
- 8.4.3 INDIA
- 8.4.3.1 Favorable industrial environment and lower labor costs to drive market
- 8.4.4 AUSTRALIA
- 8.4.4.1 Strategic geographical location to foster growth
- 8.4.5 JAPAN
- 8.4.5.1 Growing geriatric population to augment growth
- 8.4.6 SOUTH KOREA
- 8.4.6.1 Initiatives for enhanced workforce, improved regulations, and R&D for new drugs to promote growth
- 8.4.7 REST OF ASIA PACIFIC
- 8.5 LATIN AMERICA
- 8.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 8.5.2 BRAZIL
- 8.5.2.1 Rapid patient enrolment and presence of highly experienced investigators for clinical trials to expedite growth
- 8.5.3 MEXICO
- 8.5.3.1 Surge in pharmaceutical goods export to promote growth
- 8.5.4 REST OF LATIN AMERICA
- 8.6 MIDDLE EAST
- 8.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 8.6.2 GCC COUNTRIES
- 8.6.2.1 Kingdom of Saudi Arabia
- 8.6.2.1.1 Growing focus on enhanced healthcare expenditure to aid market growth
- 8.6.2.2 UAE
- 8.6.2.2.1 Growing population and healthcare spending to drive market
- 8.6.2.3 Other GCC Countries
- 8.6.3 REST OF MIDDLE EAST
- 8.7 AFRICA
- 8.7.1 RISING CASES OF CANCER AND OTHER CHRONIC DISEASES TO FACILITATE GROWTH
- 8.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
9 COMPETITIVE LANDSCAPE
- 9.1 INTRODUCTION
- 9.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 9.3 REVENUE ANALYSIS
- 9.4 MARKET SHARE ANALYSIS
- 9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 9.5.1 STARS
- 9.5.2 EMERGING LEADERS
- 9.5.3 PERVASIVE PLAYERS
- 9.5.4 PARTICIPANTS
- 9.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 9.5.5.1 Company footprint
- 9.5.5.2 Service footprint
- 9.5.5.3 End-user footprint
- 9.5.5.4 Region footprint
- 9.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 9.6.1 PROGRESSIVE COMPANIES
- 9.6.2 RESPONSIVE COMPANIES
- 9.6.3 DYNAMIC COMPANIES
- 9.6.4 STARTING BLOCKS
- 9.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 9.7 BRAND/SERVICE COMPARISON
- 9.7.1 THERMO FISHER SCIENTIFIC INC.
- 9.7.2 CATALENT, INC.
- 9.7.3 LONZA
- 9.7.4 SAMSUNG BIOLOGICS
- 9.7.5 WUXI APPTEC
- 9.8 COMPANY VALUATION AND FINANCIAL METRICS
- 9.9 COMPETITIVE SCENARIO
- 9.9.1 SERVICE LAUNCHES
- 9.9.2 DEALS
- 9.9.3 EXPANSIONS
10 COMPANY PROFILES
- 10.1 KEY PLAYERS
- 10.1.1 THERMO FISHER SCIENTIFIC INC.
- 10.1.1.1 Business overview
- 10.1.1.2 Services offered
- 10.1.1.3 Recent developments
- 10.1.1.3.1 Service launches
- 10.1.1.3.2 Deals
- 10.1.1.3.3 Expansions
- 10.1.1.4 MnM view
- 10.1.1.4.1 Key strengths
- 10.1.1.4.2 Strategic choices
- 10.1.1.4.3 Weaknesses and competitive threats
- 10.1.2 LONZA
- 10.1.2.1 Business overview
- 10.1.2.2 Services offered
- 10.1.2.3 Recent developments
- 10.1.2.4 MnM view
- 10.1.2.4.1 Key strengths
- 10.1.2.4.2 Strategic choices
- 10.1.2.4.3 Weaknesses and competitive threats
- 10.1.3 CATALENT, INC.
- 10.1.3.1 Business overview
- 10.1.3.2 Services offered
- 10.1.3.3 Recent developments
- 10.1.3.3.1 Service launches
- 10.1.3.3.2 Deals
- 10.1.3.3.3 Expansions
- 10.1.3.4 MnM view
- 10.1.3.4.1 Key strengths
- 10.1.3.4.2 Strategic choices
- 10.1.3.4.3 Weaknesses and competitive threats
- 10.1.4 WUXI APPTEC
- 10.1.4.1 Business overview
- 10.1.4.2 Services offered
- 10.1.4.3 Recent developments
- 10.1.4.3.1 Deals
- 10.1.4.3.2 Expansions
- 10.1.4.4 MnM view
- 10.1.4.4.1 Key strengths
- 10.1.4.4.2 Strategic choices
- 10.1.4.4.3 Weaknesses and competitive threats
- 10.1.5 WUXI BIOLOGICS
- 10.1.5.1 Business overview
- 10.1.5.2 Services offered
- 10.1.5.3 Recent developments
- 10.1.5.3.1 Deals
- 10.1.5.3.2 Expansions
- 10.1.6 SAMSUNG BIOLOGICS
- 10.1.6.1 Business overview
- 10.1.6.2 Services offered
- 10.1.6.3 Recent developments
- 10.1.6.3.1 Deals
- 10.1.6.3.2 Expansions
- 10.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 10.1.7.1 Business overview
- 10.1.7.2 Services offered
- 10.1.7.3 Recent developments
- 10.1.7.3.1 Deals
- 10.1.7.3.2 Expansions
- 10.1.8 EVONIK INDUSTRIES AG
- 10.1.8.1 Business overview
- 10.1.8.2 Services offered
- 10.1.8.3 Recent developments
- 10.1.8.3.1 Deals
- 10.1.8.3.2 Expansions
- 10.1.9 FUJIFILM HOLDINGS CORPORATION
- 10.1.9.1 Business overview
- 10.1.9.2 Services offered
- 10.1.9.3 Recent developments
- 10.1.9.3.1 Deals
- 10.1.9.3.2 Expansions
- 10.1.10 ABBVIE INC.
- 10.1.10.1 Business overview
- 10.1.10.2 Services offered
- 10.1.10.3 Recent developments
- 10.1.10.3.1 Deals
- 10.1.10.3.2 Expansions
- 10.1.11 SIEGFRIED HOLDING AG
- 10.1.11.1 Business overview
- 10.1.11.2 Services offered
- 10.1.11.3 Recent developments
- 10.1.11.3.1 Deals
- 10.1.11.3.2 Expansions
- 10.1.12 MERCK KGAA
- 10.1.12.1 Business overview
- 10.1.12.2 Services offered
- 10.1.12.3 Recent developments
- 10.1.12.3.1 Deals
- 10.1.12.3.2 Expansions
- 10.1.13 ALMAC GROUP
- 10.1.13.1 Business overview
- 10.1.13.2 Services offered
- 10.1.13.3 Recent developments
- 10.1.13.3.1 Deals
- 10.1.13.3.2 Expansions
- 10.1.14 CHARLES RIVER LABORATORIES
- 10.1.14.1 Business overview
- 10.1.14.2 Services offered
- 10.1.14.3 Recent developments
- 10.1.14.3.1 Deals
- 10.1.14.3.2 Expansions
- 10.1.15 ASYMCHEM INC.
- 10.1.15.1 Business overview
- 10.1.15.2 Services offered
- 10.1.15.3 Recent developments
- 10.1.15.3.1 Deals
- 10.1.15.3.2 Expansions
- 10.1.16 VETTER PHARMA
- 10.1.16.1 Business overview
- 10.1.16.2 Services offered
- 10.1.16.3 Recent developments
- 10.1.16.3.1 Deals
- 10.1.16.3.2 Expansions
- 10.1.17 ALCAMI CORPORATION
- 10.1.17.1 Business overview
- 10.1.17.2 Services offered
- 10.1.17.3 Recent developments
- 10.1.17.3.1 Deals
- 10.1.17.3.2 Expansions
- 10.2 OTHER PLAYERS
- 10.2.1 PIRAMAL PHARMA SOLUTIONS
- 10.2.2 SYNGENE INTERNATIONAL LIMITED
- 10.2.3 CAMBREX CORPORATION
- 10.2.4 JUBILANT BIOSYS LTD.
- 10.2.5 YUHAN CORPORATION
- 10.2.6 PIERRE FABRE GROUP
- 10.2.7 PFIZER CENTREONE
- 10.2.8 DELPHARM
- 10.2.9 FRONTAGE LABS
- 10.2.10 SHARP SERVICES, LLC
- 10.2.11 GRAND RIVER ASEPTIC MANUFACTURING
11 APPENDIX
- 11.1 DISCUSSION GUIDE
- 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 11.3 CUSTOMIZATION OPTIONS
- 11.4 RELATED REPORTS
- 11.5 AUTHOR DETAILS
